BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
CLSA Maintains Buy on Sun Pharma
CLSA has maintained buy on Sun Pharma for target price of Rs 1,088. CLSA sees growth in FY17 EBITDA. It expects synergy benefits of $100 million-120 million from Ranbaxy in FY17. CLSA adds that India, core US & generic Gleevec launch critical. However, delay in new approvals/no Halol resolution are key risks to Sun Pharma.